IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

June 15, 2023

  • The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry partners
  • The consortium will carry out research into improving clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas

Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the Philips-coordinated IMAGIO consortium [1] of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners [2], to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas. Leading European hospitals participating in the consortium include Leiden, Maastricht, Radboud and Utrecht University Medical Centers in the Netherlands and University Hospital of Cologne in Germany.

In Europe about 2.7 million people are diagnosed with cancer each year [3]. While significant advances have been made in treatment, many approaches continue to have negative side effects, impacting healthy tissues as well as targeting the cancer itself. The aim of interventional oncology is the very precise treatment of cancer cells with small instruments supported by imaging modalities such as MRI, ultrasound and CT. Treatment is carried out through targeted surgery, radiotherapy, chemotherapy, immunotherapy, or high-intensity focused ultrasound. In addition to reducing damage to healthy tissues, expanding the use of minimally or non-invasive procedures also decreases the need for major surgery.

'By bringing together leading university medical centers, academic partners, patient and healthcare professional organizations, as well as smaller and larger companies in the medical technology and pharmaceutical industry, the IMAGIO consortium has the potential to make a significant impact on improving cancer treatment,” said Bert van Meurs, Chief Business Leader Image Guided Therapy and Chief Business Leader Precision Diagnosis (ad interim) at Royal Philips. “We’ve chosen to focus on liver and lung cancer – two leading causes of death – alongside soft tissue sarcomas, a highly aggressive form of cancer that affects a significant proportion of young individuals, causing a lot of human suffering. By advancing established treatments and developing new approaches, we aim to improve clinical outcomes.”

Specific projects taking place in the consortium include:

  • Collaboration with Radboud University Medical Center and other partners including Jansen Pharmaceutica, Pfizer, Flash Pathology, VU, ETH, ImaginAb Inc. and Eberhards Karls University Tübingen to further expand diagnosis and minimally invasive treatment of lung cancer supported by Philips' Azurion image-guided therapy platform. Read more.
  • Collaboration with Leiden and Maastricht University Medical Centers to improve the diagnosis and treatment of liver cancer using CT, ultrasound, precision marking and ablation technology.
  • Collaboration with University Medical Center Utrecht and TU Delft to improve the treatment of liver cancer through radioembolization (a type of radiation therapy) supported by hybrid imaging modalities. Read more.
  • Collaboration between University Hospital of Cologne, Profound Medical and Philips to treat soft tissue sarcomas with MR-guided high intensity focused ultrasound (MR-HIFU) in combination with Thermosome’s lead drug candidate THE001, which is a thermosensitive liposomal formulation of doxorubicin developed in soft tissue sarcoma.

[1] The IMAGIO consortium – IMaging and Advanced Guidance for workflow optimization in Interventional Oncology – includes the following partners Philips, UMC Utrecht, LUMC, University Hospital of Cologne, TU Delft, Radboudumc, Luxium Solutions, Flash Pathology, Vrije Universiteit Amsterdam, Profound Medical, Gremse-IT, Thermosome, MUMC+, Nederlandse Leverpatiënten Vereniging, Fondazione IRCCS Istituto Nazionale Dei Tumori, Eberhards Karls University Tübingen, European Cancer Patient Coalition, Stichting Longkanker Nederland, ImaginAb Inc., Pfizer Inc., Universiteit Twente, Nanovi, Turku University Hospital, SIOP Europe, Janssen Pharmaceutica; and associated partners Eidgenössische Technische Hochschule Zürich and The Newcastle Upon Tyne Hospitals NHS Foundation Trust.
[2] The industry partners are members of COCIR, EFPIA, EuropaBio and MedTech Europe.
[3] European Commission, Europe's Beating Cancer Plan https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf.

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112053. The JU receives support from the European Union’s Horizon Europe research and innovation program and life science industries represented by COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe.

Disclaimer: IMAGIO is funded by the European Union, private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

For further information, please contact:
Mark Groves
Philips Global Press Office 
Tel: +31 631 639 916  
Email: mark.groves@philips.com  

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

  • IMAGIO consortium logo (IMaging and Advanced Guidance for workflow optimization in Interventional Oncology)
  • IMAGIO partners meet for the kick-off
  • Philips Azurion Image Guided Therapy Platform


IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

THỦ THUẬT HAY

Có nên xem phim 'người lớn' trên các thiết bị Android ?

Có hàng ngàn ứng dụng xem phim khiêu dâm có sẵn trên Google Play và vô số người truy cập trình duyệt web trên Android để xem phim khiêu dâm mỗi ngày. Mặc dù xem phim cấp 3 không phải là hành vi vi phạm pháp luật, dưới

Đăng ký và sử dụng KakaoTalk trên điện thoại một cách nhanh chóng

Để sử dụng được những tính năng trên một cách đầy đủ thì bạn phải đăng ký tài khoản trên KakaoTalk.

Dưới đây cách thêm, xóa số điện thoại đăng nhập trên Facebook cực đơn giản

Số điện thoại đăng nhập trên Facebook là một trong hai cách đăng ký tài khoản, bảo mật cũng như có thể giúp người dùng tìm kiếm bạn nhanh chóng thông qua số điện thoại. Để cập nhật số điện thoại đăng nhập Facebook, bạn

Cách tạo ảnh kỷ niệm trên iPhone để bạn xem lại khoảnh khắc đáng nhớ

Bạn có thể tự tạo nội dung bộ sưu tập ảnh kỷ niệm với những sự kiện, con người, địa điểm ấn tượng trên iPhone của mình. Sau đây là cách tạo ảnh kỷ niệm trên iPhone...

Cách đổi giao diện respring trên iPhone

Màn hình respring trên iPhone đã jailbreak rất đơn giản và khá nhàm chán. Nếu vậy bạn có thể cài tweak YouRespring để đổi lại màn hình.

ĐÁNH GIÁ NHANH

Đánh giá Sony MDR XB950BT: Lựa chọn lý tưởng cho basshead

Sony MDR XB950BT hiện đang được bán tại hệ thông Mai Nguyên với giá 3.990.000...

Điều gì khiến bộ đôi Galaxy Z Fold3 5G và Z Flip3 5G trở thành những người dẫn đầu trong giới smartphone?

Là bộ đôi smartphone màn hình gập mới nhất trên thị trường smartphone thời điểm hiện tại, Galaxy Z Fold3 5G và Z Flip3 5G đang chứng minh mình đã sẵn sàng để cạnh tranh ngôi vị dẫn đầu về công nghệ với những nâng cấp